A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past

Inclusion Criteria: Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age greater than or equal to 18 years old and ≤ 75 years old at the same time of signing the informed consent. * Histologically or cytologically confirmed for HCC * Eastern Cooperative Oncology Group (ECOG) 0 to 1. * Adequate organ function as defined in protocol. Exclusion Criteria: * History of other malignancy within the past 5 years with exceptions. * Systemic chemotherapy was administered within 4 weeks prior to the first administration. * Activated symptomatic brain metastases and leptomeningeal disease. * History of hepatic encephalopathy disease in past 12 months. * Participants with symptoms and/or clinical signs and/or uncontrolled active systemic infection within 14 days prior to the first dose of study treatment. Participant has known active infection requiring parenteral antibiotic treatment.